Compare Stocks: TOVX, TVGN, ABVC, and ACTU

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$1.01 -6.5%	$1.37	$0.88 ▼ $3.40	$26.82M	0.54	153,075 shs	25,293 shs
ACTU Actuate Therapeutics	$1.11 -5.1%	$1.68	$1.03 ▼ $9.22	$26.56M	0.67	435,306 shs	155,073 shs
TOVX Theriva Biologics	$0.21 0.0%	$0.25	$0.16 ▼ $0.86	$7.09M	1.09	2.46 million shs	586,362 shs
TVGN Tevogen Bio	$7.05 +4.9%	$7.35	$3.64 ▼ $69.99	$29.75M	0.2	14,567 shs	10,664 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	-6.48%	-12.17%	-42.94%	-1.94%	-64.93%
ACTU Actuate Therapeutics	-5.13%	-5.93%	-22.92%	-63.00%	-84.73%
TOVX Theriva Biologics	0.00%	-5.79%	-16.00%	-46.10%	-50.75%
TVGN Tevogen Bio	+4.91%	+57.02%	+22.82%	+5.86%	-86.18%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$1.01 -6.5%	$1.37	$0.88 ▼ $3.40	$26.82M	0.54	153,075 shs	25,293 shs
ACTU Actuate Therapeutics	$1.11 -5.1%	$1.68	$1.03 ▼ $9.22	$26.56M	0.67	435,306 shs	155,073 shs
TOVX Theriva Biologics	$0.21 0.0%	$0.25	$0.16 ▼ $0.86	$7.09M	1.09	2.46 million shs	586,362 shs
TVGN Tevogen Bio	$7.05 +4.9%	$7.35	$3.64 ▼ $69.99	$29.75M	0.2	14,567 shs	10,664 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	-6.48%	-12.17%	-42.94%	-1.94%	-64.93%
ACTU Actuate Therapeutics	-5.13%	-5.93%	-22.92%	-63.00%	-84.73%
TOVX Theriva Biologics	0.00%	-5.79%	-16.00%	-46.10%	-50.75%
TVGN Tevogen Bio	+4.91%	+57.02%	+22.82%	+5.86%	-86.18%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	1.00	Sell	N/A	N/A
ACTU Actuate Therapeutics	2.50	Moderate Buy	$13.67	1,131.23% Upside
TOVX Theriva Biologics	3.00	Buy	$1.00	376.19% Upside
TVGN Tevogen Bio	1.50	Reduce	$100.00	1,318.44% Upside

Current Analyst Ratings Breakdown

Latest TOVX, TVGN, ABVC, and ACTU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	ACTU Actuate Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00
7/17/2026	TVGN Tevogen Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	ACTU Actuate Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/15/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/10/2026	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/29/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/18/2026	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
5/15/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/1/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	$510K	52.58	N/A	N/A	$0.52 per share	1.94
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	$0.34 per share	N/A
TOVX Theriva Biologics	N/A	N/A	N/A	N/A	$0.46 per share	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($211.84) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$7.91M	-$0.40	N/A	N/A	N/A	N/A	-62.46%	-39.99%	8/18/2026 (Estimated)
ACTU Actuate Therapeutics	-$22.23M	-$0.97	N/A	N/A	N/A	N/A	-430.93%	-180.86%	N/A
TOVX Theriva Biologics	-$23.74M	-$33.06	N/A	N/A	N/A	N/A	-178.29%	-59.96%	N/A
TVGN Tevogen Bio	-$26.27M	-$4.61	N/A	N/A	N/A	N/A	N/A	-472.77%	8/13/2026 (Estimated)

Latest TOVX, TVGN, ABVC, and ACTU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2026	Q2 2026	ABVC ABVC BioPharma	-$0.40	N/A	N/A	N/A	$0.11 million	N/A
8/13/2026	N/A	TVGN Tevogen Bio	-$2.5350	N/A	N/A	N/A	N/A	N/A
5/18/2026	Q1 2026	ABVC ABVC BioPharma	N/A	-$0.06	N/A	-$0.06	N/A	N/A
5/15/2026	Q1 2026	TVGN Tevogen Bio	-$2.64	-$1.61	+$1.03	-$1.61	N/A	N/A
5/14/2026	Q1 2026	ACTU Actuate Therapeutics	-$0.23	-$0.24	-$0.01	-$0.24	N/A	N/A
5/5/2026	Q1 2026	TOVX Theriva Biologics	N/A	-$0.05	N/A	-$0.05	N/A	$0.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A
TOVX Theriva Biologics	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.12	0.12
ACTU Actuate Therapeutics	N/A	1.80	1.80
TOVX Theriva Biologics	0.11	1.63	1.63
TVGN Tevogen Bio	N/A	0.29	0.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
ACTU Actuate Therapeutics	N/A
TOVX Theriva Biologics	6.17%
TVGN Tevogen Bio	N/A

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	19.00%
ACTU Actuate Therapeutics	57.98%
TOVX Theriva Biologics	1.02%
TVGN Tevogen Bio	70.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	26.55 million	21.51 million	Not Optionable
ACTU Actuate Therapeutics	10	23.93 million	10.05 million	N/A
TOVX Theriva Biologics	20	33.74 million	33.40 million	Not Optionable
TVGN Tevogen Bio	3	4.22 million	1.24 million	N/A

TOVX, TVGN, ABVC, and ACTU Headlines

Recent News About These Companies

Tevogen Bio Holdings Rebrands as Tevogen Inc.

July 30 at 9:11 AM | tipranks.com

Tevogen Bio Holdings Corporate Event Calendar | NASDAQ:TVGN

July 24, 2026 | benzinga.com

Tevogen Bio (NASDAQ:TVGN) Shares Up 4.4% - Still a Buy?

July 22, 2026 | americanbankingnews.com

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

July 13, 2026 | globenewswire.com

Tevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services Initiative

June 10, 2026 | finanznachrichten.de

Tevogen Bio Holdings Inc. Announces William Keane as Interim Head of New Healthcare Services Initiative, Exploring MSO and CRO Acquisitions

June 9, 2026 | quiverquant.comQ

Tevogen Announces Formation of a Healthcare Services Initiative

June 9, 2026 | globenewswire.com

Tevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

May 28, 2026 | finanznachrichten.de

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 ...

May 28, 2026 | enidnews.comE

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

May 28, 2026 | globenewswire.com

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services ...

May 21, 2026 | caledonianrecord.comC

Tevogen Bio Holdings Inc. Signs Non-Binding Letter of Intent to Explore Strategic Healthcare Transaction

May 21, 2026 | quiverquant.comQ

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

May 21, 2026 | globenewswire.com

Tevogen Bio Holdings Inc. Reports Significant Operational Improvements and Strategic Growth Initiatives

May 18, 2026 | quiverquant.comQ

Letter to Shareholders from CEO Dr. Ryan Saadi

May 18, 2026 | globenewswire.com

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest ...

May 12, 2026 | caledonianrecord.comC

Tevogen Bio Holdings Inc. Secures $3 Million PIPE Financing from The Patel Family, LLP

May 12, 2026 | quiverquant.comQ

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

May 12, 2026 | globenewswire.com

Tevogen (TVGN) Soars 11% as Firm Gears Up for AI Training Commercialization

May 5, 2026 | finance.yahoo.com

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

April 27, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TOVX, TVGN, ABVC, and ACTU Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$1.01 -0.07 (-6.48%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$1.01 +0.00 (+0.50%)

As of 07/31/2026 07:34 PM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Actuate Therapeutics NASDAQ:ACTU

$1.11 -0.06 (-5.13%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$1.11 0.00 (0.00%)

As of 07/31/2026 07:34 PM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Theriva Biologics NYSEAMERICAN:TOVX

$0.21 0.00 (-0.05%)

Closing price 07/31/2026 04:10 PM Eastern

Extended Trading

$0.21 +0.00 (+1.43%)

As of 07/31/2026 07:34 PM Eastern

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

Tevogen Bio NASDAQ:TVGN

$7.05 +0.33 (+4.91%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$6.84 -0.21 (-2.91%)

As of 07/31/2026 06:15 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TOVX, TVGN, ABVC, and ACTU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TOVX, TVGN, ABVC, and ACTU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TOVX, TVGN, ABVC, and ACTU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TOVX, TVGN, ABVC, and ACTU Company Descriptions

ABVC BioPharma NASDAQ:ABVC

Actuate Therapeutics NASDAQ:ACTU

Theriva Biologics NYSEAMERICAN:TOVX

Tevogen Bio NASDAQ:TVGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TOVX, TVGN, ABVC, and ACTU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TOVX, TVGN, ABVC, and ACTU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TOVX, TVGN, ABVC, and ACTU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TOVX, TVGN, ABVC, and ACTU Company Descriptions

ABVC BioPharma NASDAQ:ABVC

Actuate Therapeutics NASDAQ:ACTU

Theriva Biologics NYSEAMERICAN:TOVX

Tevogen Bio NASDAQ:TVGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools